18 Feb 2019 10:59
18 February 2019
Yourgene Health plc
("Yourgene" or the "Company")
Issue of Equity
Manchester, UK - 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces that, following the announcement made by the Company earlier today, it has now made application to the London Stock Exchange to admit the 41,356,165 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 22 February 2019. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 458,999,688 ordinary shares of 0.1p each. None of the ordinary shares are held in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
| |
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@yourgene-health.com
| Tel: +44 (0)161 667 1053
|
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie
| Tel: +44 (0)20 7213 0880 |
finnCap (Broker) Geoff Nash / Matthew Radley (Corporate Finance) Tim Redfern / Sunila de Silva (ECM)
| Tel: +44 (0)20 7220 0500 |
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock yourgene@vigocomms.com
| Tel: +44 (0)20 7390 0234
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.
Yourgene Health's first commercialised products are non-invasive prenatal tests (NIPT) for Down's syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health's customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.